Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- befree-20150227 importedOn "2015-02-27" NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion wasGeneratedBy ECO_0000203 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion wasDerivedFrom befree-20150227 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion SIO_000772 23801497 NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion evidence source_evidence_literature NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.